特奈普酶与阿替普酶治疗急性缺血性中风的比较分析:印度东部多中心观察研究

Arpan Dutta, Subhadeep Gupta, U. Chakraborty, Chayan Mondal, Soumozit Banerjee, Deep Das, S. Jatua, Susanta Chakrabarty, Samiran Misra, Jishnu Bhattacharya, Samir K. Datta, Somnath Ghosh, Debasish Sanyal, Arnab Sarkar, B. Ray
{"title":"特奈普酶与阿替普酶治疗急性缺血性中风的比较分析:印度东部多中心观察研究","authors":"Arpan Dutta, Subhadeep Gupta, U. Chakraborty, Chayan Mondal, Soumozit Banerjee, Deep Das, S. Jatua, Susanta Chakrabarty, Samiran Misra, Jishnu Bhattacharya, Samir K. Datta, Somnath Ghosh, Debasish Sanyal, Arnab Sarkar, B. Ray","doi":"10.4103/aian.aian_59_24","DOIUrl":null,"url":null,"abstract":"\n \n \n Tenecteplase is used as an alternative to alteplase and is considered noninferior for thrombolysis in acute ischemic stroke.\n \n \n \n To compare the effectiveness and adverse effects of tenecteplase and alteplase in the real-world management of acute ischemic stroke.\n \n \n \n In this retrospective observational study, we collected data from acute ischemic stroke patients admitted in six hospitals in West Bengal, India, and were thrombolysed with tenecteplase or alteplase between July 2021 and June 2022. Demographic data, baseline parameters, hospital course, and 3-month follow-up data were collected. The percentage of patients achieving a score of 0–2 in the modified Ranking scale at 3 months, rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the two thrombolytic agents.\n \n \n \n A total of 162 patients were initially included in this study. Eight patients were excluded due to unavailability of follow-up data. Among the remaining patients, 71 patients received tenecteplase and 83 patients received alteplase. There was no statistically significant difference between tenecteplase and alteplase with respect to the percentage of patients achieving functional independence (modified Rankin scale score 0–2) at 3 months (53.5% vs. 60.2%, P = 0.706), rate of symptomatic intracranial hemorrhage (5.6% vs. 10.8%, P = 0.246), and all-cause mortality at 3 months (11.3% vs. 15.7%, P = 0.628).\n \n \n \n The effectiveness of tenecteplase is comparable to alteplase in the real-world management of acute ischemic stroke. Symptomatic intracranial hemorrhage and all-cause mortality rates are also similar in real-world practice.\n","PeriodicalId":504920,"journal":{"name":"Annals of Indian Academy of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative Analysis of Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Multicentric Observational Study from Eastern India\",\"authors\":\"Arpan Dutta, Subhadeep Gupta, U. Chakraborty, Chayan Mondal, Soumozit Banerjee, Deep Das, S. Jatua, Susanta Chakrabarty, Samiran Misra, Jishnu Bhattacharya, Samir K. Datta, Somnath Ghosh, Debasish Sanyal, Arnab Sarkar, B. Ray\",\"doi\":\"10.4103/aian.aian_59_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Tenecteplase is used as an alternative to alteplase and is considered noninferior for thrombolysis in acute ischemic stroke.\\n \\n \\n \\n To compare the effectiveness and adverse effects of tenecteplase and alteplase in the real-world management of acute ischemic stroke.\\n \\n \\n \\n In this retrospective observational study, we collected data from acute ischemic stroke patients admitted in six hospitals in West Bengal, India, and were thrombolysed with tenecteplase or alteplase between July 2021 and June 2022. Demographic data, baseline parameters, hospital course, and 3-month follow-up data were collected. The percentage of patients achieving a score of 0–2 in the modified Ranking scale at 3 months, rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the two thrombolytic agents.\\n \\n \\n \\n A total of 162 patients were initially included in this study. Eight patients were excluded due to unavailability of follow-up data. Among the remaining patients, 71 patients received tenecteplase and 83 patients received alteplase. There was no statistically significant difference between tenecteplase and alteplase with respect to the percentage of patients achieving functional independence (modified Rankin scale score 0–2) at 3 months (53.5% vs. 60.2%, P = 0.706), rate of symptomatic intracranial hemorrhage (5.6% vs. 10.8%, P = 0.246), and all-cause mortality at 3 months (11.3% vs. 15.7%, P = 0.628).\\n \\n \\n \\n The effectiveness of tenecteplase is comparable to alteplase in the real-world management of acute ischemic stroke. Symptomatic intracranial hemorrhage and all-cause mortality rates are also similar in real-world practice.\\n\",\"PeriodicalId\":504920,\"journal\":{\"name\":\"Annals of Indian Academy of Neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Indian Academy of Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/aian.aian_59_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Indian Academy of Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/aian.aian_59_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

替奈普酶是阿替普酶的替代品,被认为在急性缺血性中风溶栓治疗中不具劣效。 在实际治疗急性缺血性脑卒中的过程中,比较替奈普酶和阿替普酶的有效性和不良反应。 在这项回顾性观察研究中,我们收集了印度西孟加拉邦六家医院收治的急性缺血性脑卒中患者的数据,这些患者在 2021 年 7 月至 2022 年 6 月期间接受了替奈普酶或阿替普酶溶栓治疗。研究人员收集了患者的人口统计学数据、基线参数、住院过程和 3 个月的随访数据。两种溶栓药物的主要比较指标包括:3个月后达到改良排名量表0-2分的患者比例、无症状颅内出血率和3个月内全因死亡率。 本研究最初共纳入了 162 名患者。由于无法获得随访数据,8 名患者被排除在外。在剩下的患者中,71名患者接受了替奈普酶治疗,83名患者接受了阿替普酶治疗。在3个月时实现功能独立(改良Rankin量表评分0-2)的患者比例(53.5% vs. 60.2%,P = 0.706)、无症状颅内出血率(5.6% vs. 10.8%,P = 0.246)和3个月时全因死亡率(11.3% vs. 15.7%,P = 0.628)方面,替奈替普酶和阿替普酶之间的差异无统计学意义。 在急性缺血性脑卒中的实际治疗中,替奈普酶的疗效与阿替普酶相当。在现实世界中,症状性颅内出血率和全因死亡率也相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative Analysis of Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Multicentric Observational Study from Eastern India
Tenecteplase is used as an alternative to alteplase and is considered noninferior for thrombolysis in acute ischemic stroke. To compare the effectiveness and adverse effects of tenecteplase and alteplase in the real-world management of acute ischemic stroke. In this retrospective observational study, we collected data from acute ischemic stroke patients admitted in six hospitals in West Bengal, India, and were thrombolysed with tenecteplase or alteplase between July 2021 and June 2022. Demographic data, baseline parameters, hospital course, and 3-month follow-up data were collected. The percentage of patients achieving a score of 0–2 in the modified Ranking scale at 3 months, rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the two thrombolytic agents. A total of 162 patients were initially included in this study. Eight patients were excluded due to unavailability of follow-up data. Among the remaining patients, 71 patients received tenecteplase and 83 patients received alteplase. There was no statistically significant difference between tenecteplase and alteplase with respect to the percentage of patients achieving functional independence (modified Rankin scale score 0–2) at 3 months (53.5% vs. 60.2%, P = 0.706), rate of symptomatic intracranial hemorrhage (5.6% vs. 10.8%, P = 0.246), and all-cause mortality at 3 months (11.3% vs. 15.7%, P = 0.628). The effectiveness of tenecteplase is comparable to alteplase in the real-world management of acute ischemic stroke. Symptomatic intracranial hemorrhage and all-cause mortality rates are also similar in real-world practice.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信